Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth [Yahoo! Finance]
Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results [Yahoo! Finance]
Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results
Larimar Therapeutics, Inc. (NASDAQ: LRMR) had its "outperform" rating re-affirmed by analysts at Leerink Partnrs.
Larimar Therapeutics, Inc. (NASDAQ: LRMR) is now covered by analysts at SVB Leerink LLC. They set an "outperform" rating and a $25.00 price target on the stock.